amgen
Amgen's Denosumab Approved for Cancer Patients
1:24PM 11/19/2010
Company News, Health Care, Novartis, Amgen, Stocks in the News
The FDA has approved Amgen's osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication to prevent complications such as fractures and bone pain among those patients could boost the drug's sales by billions.
Drug-makers Amgen and Johnson & Johnson are voluntarily recalling two brands of an injectable anemia medication because of the possibility that vials of it may also contain tiny glass flakes. The drug, Epoetin alfa, is marketed under the brand names Epogen and Procrit.
Amgen, the world's largest biotechnology company, reported fourth-quarter results that missed Wall Street's expectations, as a 2% increase in sales failed to translate into a stronger bottom line.
Health-Care Sector Appears to Rally As Reform Chances Dim
8:15PM 1/20/2010
Health Care, Genzyme Corporation , Bristol-Myers Squibb, CIGNA Corporation, Sanofi Aventis, Merck, GlaxoSmithKline, Amgen, Eli Lilly
President Obama can't be pleased by the loss of a Democratic Senate seat which jeopardizes passage of his cherished health-care reform. The news, however, appears to have fueled a mini stock rally in the health-care and pharma sectors wary of how any reform would affect their businesses. The uptrend is expected to continue.
Abbott, Amgen Are On the Prowl with Small Deals
5:00PM 12/15/2009
Acquisitions and deals are always a risky business, especially in the pharmaceuticals industry. Just today, Elan Corp. (ELN) and Gilead Sciences (GILD) discovered the price of such deals when both halted drug trials on compounds developed by other pharmaceutical firms. Due to safety concerns, Elan...
Pfizer may be hatching plans to sell "biosimilars," cheaper versions of biotech medicines, of drugs developed by the world's largest independent biotech Amgen. That's causing concern not just at Amgen, but at other biotechs that fear such competition.
Amgen's stock buyback plan could boost shares
11:15AM 12/08/2009
Amgen (AMGN) said on Monday its board of directors had authorized repurchases of up to $5 billion in company common stock. That's on top of the approximately $1.2 billion remaining under its previous stock buyback plan. This new authorization, Amgen said in a statement, reflects its confidence in...
It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen (AMGN) just can't catch a break, nor for that matter, create one. Recently, Amgen was hit with a double whammy -- a lawsuit and an unfavorable study of the drug. On Tuesday, yet another study confirmed that cancer patients...
Drugmaker Amgen (AMGN) did not win the Food & Drug Administration's approval on Monday for its experimental osteoporosis treatment denosumab. Amgen, based in Thousand Oaks, Calif., had been banking on the drug's approval for company growth, but the FDA asked for more information before making a...
No doubt, Amgen (AMGN) and its investors would have liked the U.S. Food and Drug Administration's health panel proceedings to have gone differently. The good news coming out of the panel, held on Thursday, was that Amgen's highly anticipated bone drug, denosumab, benefits patients with...
More Stories
Next Page →Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.10 | -0.09 -1.04% | 158.19M | |
| 2.20 | +0.26 +13.14% | 95.52M | |
| 18.90 | -0.24 -1.23% | 26.45M | |
| 12.41 | -0.28 -2.21% | 25.99M |
% Gainers
| 32.62 | +8.72 +36.49% | 14.25M | |
| 89.53 | +13.14 +17.20% | 9.05M | |
| 2.20 | +0.26 +13.14% | 95.52M | |
| 10.52 | +1.12 +11.91% | 2.68M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Bernanke: Weak housing has hurt consumer...
- Turbo-traders take Bank of America for a ride
- Greek PM vows to rescue bailout deal
- Stocks fall sharply as Greek deal is held up
- Trade deficit widens to $48.8 billion in...
- Feds investigate door fires in 2007 Camrys,...
- NYSE Euronext profit down on blocked merger...
- Obama call for manufacturing revival a tough...
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
- 2011 Trade Deficit Hits 3-Year High, Over $550 Billion
- Today’s Best Market Rumors (2/10/2012) Apple iPad, Google Entertainment
- Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF, TRLG)
- Morning Wire — US Stock-Index Futures Down Sharply
Follow Us
